BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 2014;11:1120-9. [PMID: 25102221 DOI: 10.1513/AnnalsATS.201402-050AS] [Cited by in Crossref: 111] [Cited by in F6Publishing: 57] [Article Influence: 15.9] [Reference Citation Analysis]
Number Citing Articles
1 Goodyear MC, Garnier NE, Levesque RC, Khursigara CM. Liverpool Epidemic Strain Isolates of Pseudomonas aeruginosa Display High Levels of Antimicrobial Resistance during Both Planktonic and Biofilm Growth. Microbiol Spectr 2022;:e0102422. [PMID: 35658710 DOI: 10.1128/spectrum.01024-22] [Reference Citation Analysis]
2 Peri C, Gori A, Gagni P, Sola L, Girelli D, Sottotetti S, Cariani L, Chiari M, Cretich M, Colombo G. Evolving serodiagnostics by rationally designed peptide arrays: the Burkholderia paradigm in Cystic Fibrosis. Sci Rep 2016;6:32873. [PMID: 27615705 DOI: 10.1038/srep32873] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
3 Rouard C, Garnier F, Leraut J, Lepainteur M, Rahajamananav L, Languepin J, Ploy MC, Bourgeois-Nicolaos N, Doucet-Populaire F. Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient. Antimicrob Agents Chemother 2018;62:e00720-18. [PMID: 30275089 DOI: 10.1128/AAC.00720-18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
4 Perry EK, Meirelles LA, Newman DK. From the soil to the clinic: the impact of microbial secondary metabolites on antibiotic tolerance and resistance. Nat Rev Microbiol 2021. [PMID: 34531577 DOI: 10.1038/s41579-021-00620-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Song J, Cortez‐jugo C, Shirbin SJ, Lin Z, Pan S, Qiao GG, Caruso F. Immobilization and Intracellular Delivery of Structurally Nanoengineered Antimicrobial Peptide Polymers Using Polyphenol‐Based Capsules. Adv Funct Materials 2022;32:2107341. [DOI: 10.1002/adfm.202107341] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Garcia-Clemente M, de la Rosa D, Máiz L, Girón R, Blanco M, Olveira C, Canton R, Martinez-García MA. Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases. J Clin Med 2020;9:E3800. [PMID: 33255354 DOI: 10.3390/jcm9123800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Nielsen SM, Nørskov-Lauritsen N, Bjarnsholt T, Meyer RL. Achromobacter Species Isolated from Cystic Fibrosis Patients Reveal Distinctly Different Biofilm Morphotypes. Microorganisms 2016;4:E33. [PMID: 27681927 DOI: 10.3390/microorganisms4030033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
8 Malhotra S, Hayes D Jr, Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clin Microbiol Rev 2019;32:e00138-18. [PMID: 31142499 DOI: 10.1128/CMR.00138-18] [Cited by in Crossref: 88] [Cited by in F6Publishing: 56] [Article Influence: 29.3] [Reference Citation Analysis]
9 Wolter DJ, Scott A, Armbruster CR, Whittington D, Edgar JS, Qin X, Buccat AM, McNamara S, Blackledge M, Waalkes A, Salipante SJ, Ernst RK, Hoffman LR. Repeated isolation of an antibiotic-dependent and temperature-sensitive mutant of Pseudomonas aeruginosa from a cystic fibrosis patient. J Antimicrob Chemother 2021;76:616-25. [PMID: 33259594 DOI: 10.1093/jac/dkaa482] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Nguyen M, Sharma A, Wu W, Gomi R, Sung B, Hospodsky D, Angenent LT, Worgall S. The fermentation product 2,3-butanediol alters P. aeruginosa clearance, cytokine response and the lung microbiome. ISME J 2016;10:2978-83. [PMID: 27177192 DOI: 10.1038/ismej.2016.76] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
11 Rumpf C, Lange J, Schwartbeck B, Kahl BC. Staphylococcus aureus and Cystic Fibrosis-A Close Relationship. What Can We Learn from Sequencing Studies? Pathogens 2021;10:1177. [PMID: 34578208 DOI: 10.3390/pathogens10091177] [Reference Citation Analysis]
12 Burgel PR, Paugam A, Hubert D, Martin C. Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infect Drug Resist 2016;9:229-38. [PMID: 27703383 DOI: 10.2147/IDR.S63621] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
13 Saeed A, Bosch A, Bettiol M, Nossa González DL, Erben MF, Lamberti Y. Novel Guanidine Compound against Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species. Molecules 2018;23:E1158. [PMID: 29751676 DOI: 10.3390/molecules23051158] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
14 Zemanick ET, Hoffman LR. Cystic Fibrosis: Microbiology and Host Response. Pediatr Clin North Am 2016;63:617-36. [PMID: 27469179 DOI: 10.1016/j.pcl.2016.04.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
15 Fusco NM, Meaney CJ, Wells C, Frederick CA, Prescott WA Jr. Vancomycin Versus Vancomycin Plus Rifampin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis. J Pediatr Pharmacol Ther 2018;23:125-31. [PMID: 29720914 DOI: 10.5863/1551-6776-23.2.125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Tracy M, Cogen J, Hoffman LR. The pediatric microbiome and the lung. Curr Opin Pediatr 2015;27:348-55. [PMID: 25888147 DOI: 10.1097/MOP.0000000000000212] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Currie G, Tai A, Snelling T, Schultz A. Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians. BMJ Open Respir Res 2021;8:e000956. [PMID: 34266854 DOI: 10.1136/bmjresp-2021-000956] [Reference Citation Analysis]
18 Kiefer A, Bogdan C, Melichar VO. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm Med 2018;18:20. [PMID: 29370836 DOI: 10.1186/s12890-018-0588-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Moriano A, Serra DO, Hoard A, Montaña S, Degrossi J, Bonomo RA, Papp-Wallace KM, Ramirez MS. Staphylococcus aureus Potentiates the Hemolytic Activity of Burkholderia cepacia Complex (Bcc) Bacteria. Curr Microbiol 2021;78:1864-70. [PMID: 33770213 DOI: 10.1007/s00284-021-02458-0] [Reference Citation Analysis]
20 Yeaman MR, Filler SG, Chaili S, Barr K, Wang H, Kupferwasser D, Hennessey JP Jr, Fu Y, Schmidt CS, Edwards JE Jr, Xiong YQ, Ibrahim AS. Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection. Proc Natl Acad Sci U S A 2014;111:E5555-63. [PMID: 25489065 DOI: 10.1073/pnas.1415610111] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
21 Schwarz C, Taccetti G, Burgel P, Mulrennan S. Tobramycin safety and efficacy review article. Respiratory Medicine 2022. [DOI: 10.1016/j.rmed.2022.106778] [Reference Citation Analysis]
22 Feigelman R, Kahlert CR, Baty F, Rassouli F, Kleiner RL, Kohler P, Brutsche MH, von Mering C. Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details. Microbiome 2017;5:20. [PMID: 28187782 DOI: 10.1186/s40168-017-0234-1] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 11.4] [Reference Citation Analysis]
23 Kiedrowski MR, Gaston JR, Kocak BR, Coburn SL, Lee S, Pilewski JM, Myerburg MM, Bomberger JM. Staphylococcus aureus Biofilm Growth on Cystic Fibrosis Airway Epithelial Cells Is Enhanced during Respiratory Syncytial Virus Coinfection. mSphere 2018;3:e00341-18. [PMID: 30111629 DOI: 10.1128/mSphere.00341-18] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
24 Smith S, Waters V, Jahnke N, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2020;6:CD009528. [PMID: 32520436 DOI: 10.1002/14651858.CD009528.pub5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Neubauer C, Kasi AS, Grahl N, Sessions AL, Kopf SH, Kato R, Hogan DA, Newman DK. Refining the Application of Microbial Lipids as Tracers of Staphylococcus aureus Growth Rates in Cystic Fibrosis Sputum. J Bacteriol 2018;200:e00365-18. [PMID: 30249710 DOI: 10.1128/JB.00365-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
26 Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2017;10:CD009528. [PMID: 28981972 DOI: 10.1002/14651858.CD009528.pub4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
27 Park AYJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. Antimicrob Agents Chemother 2018;62:e00550-18. [PMID: 29914949 DOI: 10.1128/AAC.00550-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
28 Maiden MM, Waters CM. Triclosan depletes the membrane potential in Pseudomonas aeruginosa biofilms inhibiting aminoglycoside induced adaptive resistance. PLoS Pathog 2020;16:e1008529. [PMID: 33125434 DOI: 10.1371/journal.ppat.1008529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Cho WK, Lee CG, Kim LK. COPD as a Disease of Immunosenescence. Yonsei Med J 2019;60:407-13. [PMID: 31016901 DOI: 10.3349/ymj.2019.60.5.407] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
30 Sousa SA, Morad M, Feliciano JR, Pita T, Nady S, El-Hennamy RE, Abdel-Rahman M, Cavaco J, Pereira L, Barreto C, Leitão JH. The Burkholderia cenocepacia OmpA-like protein BCAL2958: identification, characterization, and detection of anti-BCAL2958 antibodies in serum from B. cepacia complex-infected Cystic Fibrosis patients. AMB Express 2016;6:41. [PMID: 27325348 DOI: 10.1186/s13568-016-0212-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
31 Muirhead CA, Sanford JN, McCullar BG, Nolt D, MacDonald KD. One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation. Clin Med Insights Pediatr 2016;10:57-65. [PMID: 27429564 DOI: 10.4137/CMPed.S38336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 West NE, Flume PA. Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Rev Respir Med 2018;12:585-93. [PMID: 29855230 DOI: 10.1080/17476348.2018.1483723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
33 Manos J. Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections. Microorganisms 2021;9:1874. [PMID: 34576767 DOI: 10.3390/microorganisms9091874] [Reference Citation Analysis]
34 Meirelles LA, Perry EK, Bergkessel M, Newman DK. Bacterial defenses against a natural antibiotic promote collateral resilience to clinical antibiotics. PLoS Biol 2021;19:e3001093. [PMID: 33690640 DOI: 10.1371/journal.pbio.3001093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Rogers GB, Narkewicz MR, Hoffman LR. The CF gastrointestinal microbiome: Structure and clinical impact. Pediatr Pulmonol 2016;51:S35-44. [PMID: 27662102 DOI: 10.1002/ppul.23544] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
36 Beaudoin T, Stone TA, Glibowicka M, Adams C, Yau Y, Ahmadi S, Bear CE, Grasemann H, Waters V, Deber CM. Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms. Sci Rep 2018;8:14728. [PMID: 30283025 DOI: 10.1038/s41598-018-33016-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
37 Dugger DT, Fung M, Zlock L, Caldera S, Sharp L, Hays SR, Singer JP, Leard LE, Golden JA, Shah RJ, Kukreja J, Gordon E, Finkbeiner W, Kleinhenz ME, Langelier C, Greenland JR. Cystic Fibrosis Lung Transplant Recipients Have Suppressed Airway Interferon Responses during Pseudomonas Infection. Cell Rep Med 2020;1:100055. [PMID: 32754722 DOI: 10.1016/j.xcrm.2020.100055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc 2014;11:1298-306. [PMID: 25167882 DOI: 10.1513/AnnalsATS.201405-203AS] [Cited by in Crossref: 56] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
39 Jurado-Martín I, Sainz-Mejías M, McClean S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int J Mol Sci 2021;22:3128. [PMID: 33803907 DOI: 10.3390/ijms22063128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
40 Nielsen SM, Meyer RL, Nørskov-Lauritsen N. Differences in Gene Expression Profiles between Early and Late Isolates in Monospecies Achromobacter Biofilm. Pathogens 2017;6:E20. [PMID: 28534862 DOI: 10.3390/pathogens6020020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
41 Gade PAV, Olsen TB, Jensen PØ, Kolpen M, Høiby N, Henneberg KÅ, Sams T. Modelling of ciprofloxacin killing enhanced by hyperbaric oxygen treatment in Pseudomonas aeruginosa PAO1 biofilms. PLoS One 2018;13:e0198909. [PMID: 29902223 DOI: 10.1371/journal.pone.0198909] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
42 Nelson MT, Pope CE, Marsh RL, Wolter DJ, Weiss EJ, Hager KR, Vo AT, Brittnacher MJ, Radey MC, Hayden HS, Eng A, Miller SI, Borenstein E, Hoffman LR. Human and Extracellular DNA Depletion for Metagenomic Analysis of Complex Clinical Infection Samples Yields Optimized Viable Microbiome Profiles. Cell Rep 2019;26:2227-2240.e5. [PMID: 30784601 DOI: 10.1016/j.celrep.2019.01.091] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
43 Tom SK, Yau YC, Beaudoin T, LiPuma JJ, Waters V. Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients. Antimicrob Agents Chemother 2016;60:650-2. [PMID: 26525791 DOI: 10.1128/AAC.02240-15] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
44 Morris AJ, Jackson L, Cw Yau Y, Reichhardt C, Beaudoin T, Uwumarenogie S, Guttman KM, Lynne Howell P, Parsek MR, Hoffman LR, Nguyen D, DiGiandomenico A, Guttman DS, Wozniak DJ, Waters VJ. The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis. NPJ Biofilms Microbiomes 2021;7:63. [PMID: 34349133 DOI: 10.1038/s41522-021-00234-3] [Reference Citation Analysis]
45 Murray MA, Chotirmall SH. The Impact of Immunosenescence on Pulmonary Disease. Mediators Inflamm 2015;2015:692546. [PMID: 26199462 DOI: 10.1155/2015/692546] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
46 Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16:174. [PMID: 27919253 DOI: 10.1186/s12890-016-0339-5] [Cited by in Crossref: 161] [Cited by in F6Publishing: 142] [Article Influence: 26.8] [Reference Citation Analysis]
47 Secor PR, Burgener EB, Kinnersley M, Jennings LK, Roman-Cruz V, Popescu M, Van Belleghem JD, Haddock N, Copeland C, Michaels LA, de Vries CR, Chen Q, Pourtois J, Wheeler TJ, Milla CE, Bollyky PL. Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections. Front Immunol 2020;11:244. [PMID: 32153575 DOI: 10.3389/fimmu.2020.00244] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
48 Scribner MR, Santos-Lopez A, Marshall CW, Deitrick C, Cooper VS. Parallel Evolution of Tobramycin Resistance across Species and Environments. mBio 2020;11:e00932-20. [PMID: 32457248 DOI: 10.1128/mBio.00932-20] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
49 Maiden MM, Hunt AMA, Zachos MP, Gibson JA, Hurwitz ME, Mulks MH, Waters CM. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms. Antimicrob Agents Chemother 2018;62:e00146-18. [PMID: 29661867 DOI: 10.1128/AAC.00146-18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
50 Radlinski LC, Rowe SE, Brzozowski R, Wilkinson AD, Huang R, Eswara P, Conlon BP. Chemical Induction of Aminoglycoside Uptake Overcomes Antibiotic Tolerance and Resistance in Staphylococcus aureus. Cell Chem Biol 2019;26:1355-1364.e4. [PMID: 31402316 DOI: 10.1016/j.chembiol.2019.07.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
51 Ribeiro JD, Fischer GB. Chronic obstructive pulmonary diseases in children. Jornal de Pediatria (Versão em Português) 2015;91:S11-25. [DOI: 10.1016/j.jpedp.2015.09.007] [Reference Citation Analysis]
52 Ahonen MJR, Dorrier JM, Schoenfisch MH. Antibiofilm Efficacy of Nitric Oxide-Releasing Alginates against Cystic Fibrosis Bacterial Pathogens. ACS Infect Dis 2019;5:1327-35. [PMID: 31136714 DOI: 10.1021/acsinfecdis.9b00016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
53 Maiden MM, Zachos MP, Waters CM. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential. J Antimicrob Chemother 2019;74:894-906. [PMID: 30624737 DOI: 10.1093/jac/dky545] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
54 Treffon J, Fotiadis SA, van Alen S, Becker K, Kahl BC. The Virulence Potential of Livestock-Associated Methicillin-Resistant Staphylococcus aureus Cultured from the Airways of Cystic Fibrosis Patients. Toxins (Basel) 2020;12:E360. [PMID: 32486247 DOI: 10.3390/toxins12060360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Briot T, Kolenda C, Ferry T, Medina M, Laurent F, Leboucher G, Pirot F; PHAGEinLYON study group. Paving the way for phage therapy using novel drug delivery approaches. J Control Release 2022;347:414-24. [PMID: 35569589 DOI: 10.1016/j.jconrel.2022.05.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Banjar H, Al-Qahtani H, Yasin W, Al-Wgait W, Al-Amer H, Raja R, Al-Nakhli A, Karkour K. The first report of Methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) patients in Saudi Arabia. Int J Pediatr Adolesc Med 2020;7:186-90. [PMID: 33319017 DOI: 10.1016/j.ijpam.2019.10.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Leal T, Bergamini G, Huaux F, Panin N, Noel S, Dhooghe B, Haaf JB, Mauri P, Motta S, Di Silvestre D, Melotti P, Sorio C. Azithromycin Attenuates Pseudomonas-Induced Lung Inflammation by Targeting Bacterial Proteins Secreted in the Cultured Medium. Front Immunol 2016;7:499. [PMID: 27895643 DOI: 10.3389/fimmu.2016.00499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
58 Hector A, Frey N, Hartl D. Update on host-pathogen interactions in cystic fibrosis lung disease. Mol Cell Pediatr 2016;3:12. [PMID: 26905568 DOI: 10.1186/s40348-016-0039-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
59 Bernier SP, Son S, Surette MG. The Mla Pathway Plays an Essential Role in the Intrinsic Resistance of Burkholderia cepacia Complex Species to Antimicrobials and Host Innate Components. J Bacteriol 2018;200:e00156-18. [PMID: 29986943 DOI: 10.1128/JB.00156-18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
60 Martin I, Waters V, Grasemann H. Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. Int J Mol Sci 2021;22:2155. [PMID: 33671516 DOI: 10.3390/ijms22042155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
61 Leung SS, Parumasivam T, Gao FG, Carrigy NB, Vehring R, Finlay WH, Morales S, Britton WJ, Kutter E, Chan HK. Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections. Pharm Res 2016;33:1486-96. [PMID: 26928668 DOI: 10.1007/s11095-016-1892-6] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 12.2] [Reference Citation Analysis]
62 Ranzenbacher L, Song Y, Merchant A, Middleton PG. Intermittent colonisation with Methicillin-Resistant Staphylococcal aureus can be eradicated from the Airways of Adults with Cystic Fibrosis. Antibiotics (Basel) 2019;8:E113. [PMID: 31405052 DOI: 10.3390/antibiotics8030113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Pettit RS, Peters SJ, McDade EJ, Kreilein K, Patel R, Epps K, Kittell F, Duval MA, Zobell JT. Vancomycin Dosing and Monitoring in the Treatment of Cystic Fibrosis: Results of a National Practice Survey. J Pediatr Pharmacol Ther 2017;22:406-11. [PMID: 29290740 DOI: 10.5863/1551-6776-22.6.406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Malhotra S, Hayes D Jr, Wozniak DJ. Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. J Cyst Fibros 2019;18:796-803. [PMID: 31036488 DOI: 10.1016/j.jcf.2019.04.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]